Medicine & Life Sciences

1. Colorectal Neoplasms 100%
2. Acute Coronary Syndrome 71%
3. Survival 69%
4. Percutaneous Coronary Intervention 52%
5. Registries 51%
6. Colonic Neoplasms 50%
7. Confidence Intervals 34%
8. Cetuximab 33%
9. Neoplasms 31%
10. Bevacizumab 31%
11. ST Elevation Myocardial Infarction 30%
12. Progression-Free Survival 29%
13. Non-ST Elevated Myocardial Infarction 29%
14. Myocardial Infarction 28%
15. Quality Improvement 27%
16. Cardiology 24%
17. Guidelines 24%
18. Odds Ratio 22%
19. Leukemia 22%
20. American Heart Association 19%
21. Randomized Controlled Trials 18%
22. Disease-Free Survival 18%
23. Therapeutics 18%
24. Biomarkers 18%
25. Hospital Mortality 17%
26. Clinical Trials 16%
27. Unstable Angina 16%
28. regorafenib 15%
29. Recurrence 15%
30. Clopidogrel 15%
31. Circulating Tumor DNA 15%
32. Irinotecan 15%
33. Drug Therapy 14%
34. Incentive Reimbursement 14%
35. Adenocarcinoma 14%
36. Quality of Health Care 13%
37. Adjuvant Chemotherapy 13%
38. Mortality 13%
39. Guideline Adherence 13%
40. Coronary Artery Bypass 13%
41. Fluorouracil 13%
42. Oxaliplatin 13%
43. Hemorrhage 12%
44. Dietary Fats 11%
45. Troponin 11%
46. Diet 11%
47. Capecitabine 10%
48. Secondary Prevention 10%
49. Clobetasol 9%
50. Cardiogenic Shock 9%